These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
183 related items for PubMed ID: 8818851
1. A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections. Zachariah J. J Antimicrob Chemother; 1996 Jun; 37 Suppl C():103-13. PubMed ID: 8818851 [Abstract] [Full Text] [Related]
3. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. Hoepelman IM, Möllers MJ, van Schie MH, Greefhorst AP, Schlösser NJ, Sinninghe Damsté EJ, van de Moosdijk CN, Dalinghaus WH, Eland ME, Mol SJ, Rozenberg-Arska M. Int J Antimicrob Agents; 1997 Jan; 9(3):141-6. PubMed ID: 9552709 [Abstract] [Full Text] [Related]
4. Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections. Ferwerda A, Moll HA, Hop WC, Kouwenberg JM, Tjon Pian Gi CV, Robben SG, de Groot R. J Antimicrob Chemother; 2001 Apr; 47(4):441-6. PubMed ID: 11266417 [Abstract] [Full Text] [Related]
7. An open, multicentre, comparative study of the efficacy and safety of azithromycin and co-amoxiclav in the treatment of upper and lower respiratory tract infections in children. The Paediatric Azithromycin Study Group. Lauvau DV, Verbist L. J Int Med Res; 1997 Apr; 25(5):285-95. PubMed ID: 9364291 [Abstract] [Full Text] [Related]
9. Randomized, double-blind study of the clinical efficacy of 3 days of azithromycin compared with co-amoxiclav for the treatment of acute otitis media. Dunne MW, Latiolais T, Lewis B, Pistorius B, Bottenfield G, Moore WH, Garrett A, Stewart TD, Aoki J, Spiegel C, Boettger D, Shemer A. J Antimicrob Chemother; 2003 Sep; 52(3):469-72. PubMed ID: 12888586 [Abstract] [Full Text] [Related]
11. Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections. Laurent K. J Antimicrob Chemother; 1996 Jun; 37 Suppl C():115-24. PubMed ID: 8818852 [Abstract] [Full Text] [Related]
13. Comparison of azithromycin and co-amoxiclav in the treatment of otitis media in children. Daniel RR. J Antimicrob Chemother; 1993 Jun; 31 Suppl E():65-71. PubMed ID: 8396099 [Abstract] [Full Text] [Related]
14. Comparison of the efficacy, safety and tolerability of azithromycin and co-amoxiclav in the treatment of acute periapical abscesses. Adriaenssen CF. J Int Med Res; 1998 Jun; 26(5):257-65. PubMed ID: 9924711 [Abstract] [Full Text] [Related]
15. Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. Cazzola M, Vinciguerra A, Beghi GF, Paizis G, Giura R, Madonini V, Fiorentini F, Consigli GF, Tonna M, Casalini A. J Chemother; 1995 Oct; 7(5):432-41. PubMed ID: 8596127 [Abstract] [Full Text] [Related]
16. High-dosage co-amoxiclav in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women. Masterton RG, Bochsler JA. J Antimicrob Chemother; 1995 Jan; 35(1):129-37. PubMed ID: 7768760 [Abstract] [Full Text] [Related]
17. The efficacy and safety of once-daily ceftibuten compared with co-amoxiclav in the treatment of acute bacterial sinusitis. De Abate CA, Perrotta RJ, Dennington ML, Ziering RM. J Chemother; 1992 Dec; 4(6):358-63. PubMed ID: 1287138 [Abstract] [Full Text] [Related]